Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor

The anticancer drug ibrutinib (IB), also known as PCI-32765, is a compound that irreversibly inhibits Bruton’s tyrosine kinase (BTK) and was initially developed as a treatment option for B-cell lineage neoplasms. Its action is not limited to B-cells, as it is expressed in all hematopoietic lineages...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuster, Marta G., Montalbán, Mercedes G., Moulefera, Imane, Víllora, Gloria, Kaplan, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146313/
https://www.ncbi.nlm.nih.gov/pubmed/37111671
http://dx.doi.org/10.3390/pharmaceutics15041186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146313/
https://www.ncbi.nlm.nih.gov/pubmed/37111671
http://dx.doi.org/10.3390/pharmaceutics15041186

Ejemplares similares